comparemela.com

Latest Breaking News On - Nasdaq otlk - Page 1 : comparemela.com

Outlook Therapeutics (NASDAQ:OTLK) Price Target Increased to $30 00 by Analysts at HC Wainwright

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its price target upped by HC Wainwright to $30.00 in a research note released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Outlook Therapeutics’ Q2 2024 earnings at ($0.95) EPS, Q3 2024 earnings at ($1.09) […]

Outlook Therapeutics, Inc (NASDAQ:OTLK) Receives Consensus Rating of Moderate Buy from Brokerages

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The […]

Chardan Capital Comments on Outlook Therapeutics, Inc s FY2025 Earnings (NASDAQ:OTLK)

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Free Report) – Equities researchers at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Outlook Therapeutics in a research report issued to clients and investors on Thursday, February 15th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings per share of ($0.10) for the […]

Outlook Therapeutics (NASDAQ:OTLK) Upgraded by Brookline Capital Management to Buy

Brookline Capital Management upgraded shares of Outlook Therapeutics (NASDAQ:OTLK – Free Report) from a hold rating to a buy rating in a research report sent to investors on Thursday, Benzinga reports. They currently have $1.57 price target on the stock. Other research analysts also recently issued research reports about the stock. Guggenheim upgraded shares of […]

Brokerages Set Outlook Therapeutics, Inc (NASDAQ:OTLK) Target Price at $4 17

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has earned a consensus recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.